Insider Selling: Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CFO Sells $271,983.70 in Stock

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CFO William Garrett Gray sold 74,110 shares of the business’s stock in a transaction dated Thursday, February 6th. The shares were sold at an average price of $3.67, for a total value of $271,983.70. Following the completion of the sale, the chief financial officer now directly owns 1,458,644 shares of the company’s stock, valued at $5,353,223.48. The trade was a 4.84 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

William Garrett Gray also recently made the following trade(s):

• On Wednesday, December 18th, William Garrett Gray sold 268,432 shares of Checkpoint Therapeutics stock. The stock was sold at an average price of $4.01, for a total transaction of $1,076,412.32.

Checkpoint Therapeutics Price Performance

NASDAQ CKPT opened at $3.29 on Friday. The business’s fifty day moving average is $3.43 and its 200-day moving average is $2.98. The stock has a market capitalization of $160.65 million, a price-to-earnings ratio of -1.79 and a beta of 1.36. Checkpoint Therapeutics, Inc. has a one year low of $1.38 and a one year high of $4.50.

Checkpoint Therapeutics (NASDAQ:CKPT) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.08). Research analysts expect that Checkpoint Therapeutics, Inc. will post -0.94 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on CKPT shares. D. Boral Capital initiated coverage on Checkpoint Therapeutics in a report on Monday, January 13th. They issued a “buy” rating and a $9.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Checkpoint Therapeutics in a research report on Monday, December 16th. Finally, Lake Street Capital increased their price objective on shares of Checkpoint Therapeutics from $4.00 to $7.00 and gave the company a “buy” rating in a research note on Monday, December 16th.

Hedge Funds Weigh In On Checkpoint Therapeutics

Institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC increased its position in Checkpoint Therapeutics by 41.2% in the third quarter. Geode Capital Management LLC now owns 427,651 shares of the company’s stock worth $958,000 after buying an additional 124,787 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its position in Checkpoint Therapeutics by 160.0% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 130,000 shares of the company’s stock worth $291,000 after purchasing an additional 80,000 shares during the period. HB Wealth Management LLC increased its stake in shares of Checkpoint Therapeutics by 96.9% in the fourth quarter. HB Wealth Management LLC now owns 153,560 shares of the company’s stock worth $513,000 after purchasing an additional 75,560 shares in the last quarter. Walleye Capital LLC bought a new stake in shares of Checkpoint Therapeutics in the third quarter valued at approximately $148,000. Finally, Gladstone Institutional Advisory LLC lifted its stake in shares of Checkpoint Therapeutics by 75.4% during the 4th quarter. Gladstone Institutional Advisory LLC now owns 61,399 shares of the company’s stock valued at $196,000 after buying an additional 26,399 shares in the last quarter. Hedge funds and other institutional investors own 22.00% of the company’s stock.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.